Related Articles
Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy
Association between the low‑dose irinotecan regimen‑induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent